2015: Which new directions for Alzheimer's disease?
According to the World Health Organization, more than 40 million people in the world are affected with dementia. To date, 60-70% of the cases of dementia are attributed to the Alzheimer's disease (AD). This neurodegenerative disorder gradually takes place over a period of at least 20 years before th...
Zapisane w:
| 1. autor: | |
|---|---|
| Format: | Online |
| Język: | angielski |
| Wydane: |
Frontiers Media SA
2021
|
| Hasła przedmiotowe: | |
| Dostęp online: | 18144 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|
| _version_ | 1869528928313409536 |
|---|---|
| author | Ludovic Martin |
| author_browse | Ludovic Martin |
| author_facet | Ludovic Martin |
| author_sort | Ludovic Martin |
| collection | Directory of Open Access Books |
| description | According to the World Health Organization, more than 40 million people in the world are affected with dementia. To date, 60-70% of the cases of dementia are attributed to the Alzheimer's disease (AD). This neurodegenerative disorder gradually takes place over a period of at least 20 years before the onset of symptoms, which are impaired memory, apathy and depression. The characteristics of AD consist in neurofibrillary tangles (intraneuronal aggregates of hyperphosphorylated tau proteins) and senile plaques (dense extraneuronal deposits composed of amyloid ß (Aß)). The other features linked to these two core pathological hallmarks of AD are inflammation, oxidative stress, progressive synaptic and neuronal loss. In past years, some of the emerging therapeutic strategies against AD were employed to deal with the pathological hallmarks of the disease. Science teams all over the world try to restore the tau phosphorylation equilibrium. Their purpose is to interfere with the aggregation of tau and decrease its amount of proteins per se as well. Furthermore, they are trying either to stimulate the elimination processes of the aggregated tau proteins or to stop the formation of Aß peptides. This could be reached by the stimulation of the classic techniques of protein degradation such as the autophagic pathway, or by the targeted immunotherapy. In this Research Topic, we wish to summarize and review the etiology of AD and the related therapeutic opportunities for the next decades. To fully understand the precise mechanisms underlying AD, research findings, reviews, new insights and new approaches include AD and related tauopathies, tau phosphorylation balance, pharmacological compounds against AD, neuroprotection strategies and new therapeutic ways but also risk factors for AD and AD genetic information are included in this issue. |
| format | Online |
| id | doab-20.500.12854ir-39880 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Frontiers Media SA |
| publisherStr | Frontiers Media SA |
| record_format | ojs |
| spelling | doab-20.500.12854ir-398802024-04-05T17:30:06Z 2015: Which new directions for Alzheimer's disease? Ludovic Martin RC321-571 Q1-390 kinase inhibitors Therapeutics tau TREM2 Alzheimers disease microbiome Aβ peptides thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences According to the World Health Organization, more than 40 million people in the world are affected with dementia. To date, 60-70% of the cases of dementia are attributed to the Alzheimer's disease (AD). This neurodegenerative disorder gradually takes place over a period of at least 20 years before the onset of symptoms, which are impaired memory, apathy and depression. The characteristics of AD consist in neurofibrillary tangles (intraneuronal aggregates of hyperphosphorylated tau proteins) and senile plaques (dense extraneuronal deposits composed of amyloid ß (Aß)). The other features linked to these two core pathological hallmarks of AD are inflammation, oxidative stress, progressive synaptic and neuronal loss. In past years, some of the emerging therapeutic strategies against AD were employed to deal with the pathological hallmarks of the disease. Science teams all over the world try to restore the tau phosphorylation equilibrium. Their purpose is to interfere with the aggregation of tau and decrease its amount of proteins per se as well. Furthermore, they are trying either to stimulate the elimination processes of the aggregated tau proteins or to stop the formation of Aß peptides. This could be reached by the stimulation of the classic techniques of protein degradation such as the autophagic pathway, or by the targeted immunotherapy. In this Research Topic, we wish to summarize and review the etiology of AD and the related therapeutic opportunities for the next decades. To fully understand the precise mechanisms underlying AD, research findings, reviews, new insights and new approaches include AD and related tauopathies, tau phosphorylation balance, pharmacological compounds against AD, neuroprotection strategies and new therapeutic ways but also risk factors for AD and AD genetic information are included in this issue. 2021-02-11T07:33:45Z 2021-02-11T07:33:45Z 2016-01-19 14:05:46 2015 book 18144 16648714 9782889195350 https://directory.doabooks.org/handle/20.500.12854/39880 eng Frontiers Research Topics image/jpeg Attribution 4.0 International http://www.frontiersin.org/books/2015_Which_new_directions_for_Alzheimer_s_disease_/559 http://journal.frontiersin.org/researchtopic/1283/2014-what-new-directions-for-alzheimers-disease Frontiers Media SA 10.3389/978-2-88919-535-0 10.3389/978-2-88919-535-0 bf5ce210-e72e-4860-ba9b-c305640ff3ae 9782889195350 122 open access |
| spellingShingle | RC321-571 Q1-390 kinase inhibitors Therapeutics tau TREM2 Alzheimers disease microbiome Aβ peptides thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences Ludovic Martin 2015: Which new directions for Alzheimer's disease? |
| title | 2015: Which new directions for Alzheimer's disease? |
| title_full | 2015: Which new directions for Alzheimer's disease? |
| title_fullStr | 2015: Which new directions for Alzheimer's disease? |
| title_full_unstemmed | 2015: Which new directions for Alzheimer's disease? |
| title_short | 2015: Which new directions for Alzheimer's disease? |
| title_sort | 2015 which new directions for alzheimer s disease |
| topic | RC321-571 Q1-390 kinase inhibitors Therapeutics tau TREM2 Alzheimers disease microbiome Aβ peptides thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences |
| topic_facet | RC321-571 Q1-390 kinase inhibitors Therapeutics tau TREM2 Alzheimers disease microbiome Aβ peptides thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences |
| url | 18144 |
| work_keys_str_mv | AT ludovicmartin 2015whichnewdirectionsforalzheimersdisease |